- Home
- VIRT vs CELC Comparison
VIRT vs CELC Comparison
Compare VIRT & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VIRT | CELC |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.1B |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | VIRT | CELC |
|---|---|---|
| Price | $33.45 | $101.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $41.43 | ★ $100.13 |
| AVG Volume (30 Days) | 906.6K | ★ 980.5K |
| Earning Date | 01-28-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.84% | N/A |
| EPS Growth | ★ 132.69 | N/A |
| EPS | ★ 4.62 | N/A |
| Revenue | ★ $2,694,104,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.33 | ★ N/A |
| Revenue Growth | ★ 41.05 | N/A |
| 52 Week Low | $31.89 | $7.58 |
| 52 Week High | $45.77 | $112.64 |
Technical Indicators
Market Signals| Indicator | VIRT | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 39.32 | 59.21 |
| Support Level | $33.30 | $97.27 |
| Resistance Level | $34.52 | $105.14 |
| Average True Range (ATR) | 0.84 | 5.07 |
| MACD | -0.17 | -1.42 |
| Stochastic Oscillator | 13.31 | 25.67 |
Price Performance
Historical ComparisonAbout VIRT Virtu Financial Inc.
Virtu Financial Inc is a financial firm that leverages technology to deliver liquidity to the world-wide markets and transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.